All Specialties CardiologyNephrologyEndocrinologyPrimary CarePrescribing Information Previous Next Benefits of starting an SGLT2 inhibitor upon clinical diagnosis of heart failure FeaturingProfessor Subodh Verma | Canada Home List of Products HCPs All Specialties Shorts Benefits of starting an SGLT2 inhibitor upon clinical diagnosis of heart failure Related content Document ID: PC-SG-102588 Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) Clinical relationship between the heart and the kidneys Watch now Opens in new tab Read more Subodh Verma (Canada) Why should empagliflozin be your first choice in heart failure management? Watch now Opens in new tab Read more PDF Monitoring your heart failure symptoms Read more Opens in new tab Read more Subodh Verma (Canada) | Soo Yong Lee (Korea) SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 2) Watch now Opens in new tab Read more Subodh Verma (Canada) | Soo Yong Lee (Korea) SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 1) Watch now Opens in new tab
Read more Christiane Angermann (Germany) | Ricardo Carvalho (Portugal) Clinical relationship between the heart and the kidneys Watch now Opens in new tab
Read more Subodh Verma (Canada) Why should empagliflozin be your first choice in heart failure management? Watch now Opens in new tab
Read more Subodh Verma (Canada) | Soo Yong Lee (Korea) SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 2) Watch now Opens in new tab
Read more Subodh Verma (Canada) | Soo Yong Lee (Korea) SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 1) Watch now Opens in new tab